Approved by the European Medicines Agency, the U.S. Food and Drug Administration, and other regulatory bodies for both pediatric and adult XLH patients, burosumab works by blocking FGF23, thereby increasing renal phosphate reabsorption and enhancing serum levels of phosphorus and active vitamin D. Clinical trials have demonstrated that burosumab significantly improves serum phosphate levels, increases active vitamin D levels, and enhances renal phosphate reabsorption. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.